Business
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021. Krish Krishnan, Chairman and CEO at Krystal Biotech, will participate in a fireside chat, and Whitney Ijem, SVP, Strategy & Business Development, will join a panel discussion on the utility of non-traditional viral vectors. Details for the conference are as follows: Chardan Virtual 5th Annual Genetic Medicines ConferencePanel details:Gene Therapy: The Utility of Viral Vectors Non-Traditional PanelTuesday, October 5 at 9:30am ETFireside chat:Tuesday, October 5 at 11:00am ETFireside Webcast link:https://wsw.com/webcast/chard9/krys/1895635; To access live webcasts of Krystal’s presentation, please visit the Events & Presentations website page. Replays of webcasts will be available for 30 days following the event. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit http://www.krystalbio.com. CONTACTS: Investors: Whitney Ijem Krystal Biotech [email protected]: Mary Coyle TellMed Strategies [email protected] Source: Krystal Biotech, Inc. \nSource: Krystal Biotech, Inc.","length":4940,"tagName":"div"}]